# Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B

> **NCT04850950** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 240 (estimated)

## Conditions studied

- Chronic Hepatitis B
- Mother-to-Child Transmission
- Safety
- Efficacy
- Hepatitis B Virus
- Tenofovir Alafenamide Fumarate

## Interventions

- **DRUG:** Tenofovir Alafenamide fumarate 25mg Oral Tablet

## Key facts

- **NCT ID:** NCT04850950
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-26
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2021-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850950, "Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04850950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*